Tolerance spaces and behavior

Tolerance spaces used in human behavior model

Identification of control strategies to manage microbiological risks in typical pork products

Starting from 2009 a pilot project has been implemented by a local veterinary service of the Veneto region of Italy (AZ-ULSS 8) in collaboration with IZSVe (Istituto Zooprofilattico Sperimentale delle Venezie) with the aim of identifying control measures based on own-checks and official controls in order to manage microbiological risks related to traditional pork fermented sausages (Italian salami end soppresse) consumption. According to the data obtained a control strategy based on microbiological tests performed by the Competent Authority (CA) and the monitoring of the weight decrease in sausages by the food business operator (FBO) has been implemented for 2010-2011 production season

NK Cell Activation by Dendritic Cells Is Dependent on LFA-1-Mediated Induction of Calcium-Calmodulin Kinase II: Inhibition by HIV-1 Tat C-Terminal Domain

Abstract In this study, we show that binding to autologous dendritic cells (DC) induces a calcium influx in NK cells, followed by activation of the calcium-calmodulin kinase II (CAMKII), release of perforin and granzymes, and IFN-γ secretion. CAMKII is induced via LFA-1: indeed, oligomerization of LFA-1 leads to CAMKII induction in NK cells. Moreover, release of lytic enzymes and cytotoxic activity is strongly reduced by masking LFA-1 or by adding CAMKII inhibitors such as KN62 and KN93, at variance with the inactive compound KN92. NK cell-mediated lysis of DC and IFN-γ release by NK cells upon NK/DC contact are inhibited by exogenous HIV-1 Tat: the protein blocks calcium influx and impairs CAMKII activation elicited via LFA-1 in NK cells, eventually inhibiting degranulation. Experiments performed with synthetic, overlapping Tat-derived peptides showed that the C-terminal domain of the protein is responsible for inhibition. Finally, both KN62 and Tat reduced the extension of NK/DC contacts, possibly affecting NK cell granule polarization toward the target. These data provide evidence that exogenous Tat inhibits NK cell activation occurring upon contact with DC: this mechanism might contribute to the impairment of natural immunity in HIV-1 infection

Functional Brain Imaging Predicts Public Health Campaign Success

Mass media can powerfully affect health decision-making. Pre-testing through focus groups or surveys is a standard, though inconsistent, predictor of effectiveness. Converging evidence demonstrates that activity within brain systems associated with self-related processing can predict individual behavior in response to health messages. Preliminary evidence also suggests that neural activity in small groups can forecast population-level campaign outcomes. Less is known about the psychological processes that link neural activity and population-level outcomes, or how these predictions are affected by message content. We exposed 50 smokers to antismoking messages and used their aggregated neural activity within a ‘self-localizer’ defined region of medial prefrontal cortex to predict the success of the same campaign messages at the population level (n = 400 000 emails). Results demonstrate that: (i) independently localized neural activity during health message exposure complements existing self-report data in predicting population-level campaign responses (model combined R2 up to 0.65) and (ii) this relationship depends on message content—self-related neural processing predicts outcomes in response to strong negative arguments against smoking and not in response to compositionally similar neutral images. These data advance understanding of the psychological link between brain and large-scale behavior and may aid the construction of more effective media health campaigns

Surface-modified polysulfone membranes: aqueous phase oxidation via persulfate radical

Peer reviewed: YesNRC publication: Ye

Constraint Based Diagnosis Algorithms For Multiprocessors

Constraint-based diagnosis algorithms for multiprocessors A. Petri, P. Urban, J. Altmann, M. Dal Cin, E. Selenyi, K. Tilly, A. Pataricza In the latest years, new ideas appeared in system level diagnosis of multiprocessor systems. In contrary to the traditional diagnosis models (like PMC, BGM, etc.) which use strictly graph-oriented methods to determine the faulty components in a system, these new theories prefer AI-based algorithms, especially CSP methods. Syndrome decoding, the basic problem of self-diagnosis, can be easily transformed into constraints between the state of the tester and the tested components. Therefore, the diagnosis algorithm can be derived from a special constraint solving algorithm. The "benign" nature of the constraints (all their variables, representing the fault states of the components, have a very limited domain; the constraints are simple and similar to each other) reduces the algorithm's complexity so it can be converted to a powerful distributed diagnosis method with a minimal overhead. Experimental algorithms (using both centralized and distributed approach) were implemented for a Parsytec GC massively parallel multiprocessor system

Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells

Loss of the Y chromosome (LOY) is one of the most common somatic genomic alterations in hematopoietic cells in men. However, due to the high prevalence of LOY as the sole cytogenetic finding in the healthy older population, differentiating isolated LOY associated with clonal hematologic processes from aging-associated mosaicism can be difficult in the absence of definitive morphological features of disease. In the past, various investigators have proposed that a high percentage of metaphases with LOY is more likely to represent expansion of a clonal myeloid disease-associated population. It is unknown whether the proportion of metaphases with LOY is associated with the incidence of myeloid neoplasia-associated genomic alterations. To address this question, we identified marrow samples with LOY as isolated cytogenetic finding and used targeted next generation sequencing-based molecular analysis to identify common myeloid neoplasia-associated somatic mutations. Among 73 patients with median age of 75 years (range 29-90), the percentage of metaphases with LOY was <25% in 23 patients, 25-49% in 10, 50-74% in 8 and ≥75% in 32. A threshold of ≥75% LOY was significantly associated with morphologic diagnosis of myeloid neoplasm (p = 0.004). Further, ≥75% LOY was associated with a higher lifetime incidence of diagnosis of myelodysplastic syndromes (MDS; p < 0.0001), and in multivariate analysis ≥75% LOY was a statistically significant independent predictor of myeloid neoplasia [OR 6.17; 95% CI = 2.15-17.68; p = 0.0007]. Higher LOY percentage (≥75%) was associated with greater likelihood of having somatic mutations (p = 0.0009) and a higher number of these mutations (p = 0.0002). Our findings indicate that ≥75% LOY in marrow is associated with increased likelihood of molecular alterations in genes commonly seen in myeloid neoplasia and with morphologic features of MDS. These observations suggest that ≥75% LOY in bone marrow should be considered an MDS-associated cytogenetic aberration

Guiding the global evolution of cytogenetic testing for hematologic malignancies

Cytogenetics has long represented a critical component in the clinical evaluation of hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot of genome-wide copy number and structural variation, which have been shown to drive tumorigenesis, define diseases, and guide treatment. Technological innovations in sequencing have ushered in our present-day clinical genomics era. With recent publications highlighting novel sequencing technologies as alternatives to conventional cytogenetic approaches, we, an international consortium of laboratory geneticists, pathologists, and oncologists, describe herein the advantages and limitations of both conventional chromosome banding and novel sequencing technologies and share our considerations on crucial next steps to implement these novel technologies in the global clinical setting for a more accurate cytogenetic evaluation, which may provide improved diagnosis and treatment management. Considering the clinical, logistic, technical, and financial implications, we provide points to consider for the global evolution of cytogenetic testing.Fil: Akkari, Yassmine M.N.. Legacy Health; Estados UnidosFil: Baughn, Linda B.. Mayo Clinic Cancer Center; Estados UnidosFil: Dubuc, Adrian M.. Harvard Medical School; Estados UnidosFil: Smith, Adam C.. University of Toronto; CanadáFil: Mallo, Mar. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);Fil: Dal Cin, Paola. Harvard Medical School; Estados UnidosFil: Diez Campelo, Maria. Universidad de Salamanca; EspañaFil: Gallego, Marta S.. Hospital Italiano; ArgentinaFil: Granada Font, Isabel. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);Fil: Haase, Detlef T.. Universität Göttingen; AlemaniaFil: Schlegelberger, Brigitte. Leibniz Universitat Hannover; AlemaniaFil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Mecucci, Cristina. Università di Perugia; ItaliaFil: Levine, Ross L.. Memorial Sloan-kettering Cancer Center; Estados UnidosFil: Hasserjian, Robert P.. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;Fil: Solé, Francesc. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);Fil: Levy, Brynn. Columbia University; Estados UnidosFil: Xu, Xinjie. Mayo Clinic Cancer Center; Estados Unido